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The retinal pigment epithelium (RPE) interacts closely with photoreceptors to maintain visual 29 
function. In degenerative diseases such as Stargardt disease and age-related macular 30 
degeneration, the leading cause of blindness in the developed world, RPE cell loss is followed by 31 
photoreceptor cell death. RPE cells can proliferate under certain conditions, suggesting an 32 
intrinsic regenerative potential, but so far this has not been utilised therapeutically. Here, we 33 
used E2F2 to induce RPE cell replication and thereby regeneration. In both young and old (2 and 34 
18 month) wildtype mice, subretinal injection of non-integrating lentiviral vector expressing 35 
E2F2 resulted in 47% of examined RPE cells becoming BrdU positive. E2F2 induced an increase 36 
in RPE cell density of 17% compared with control vector-treated and 14% compared with 37 
untreated eyes. We also tested this approach in an inducible transgenic mouse model of RPE 38 
loss, generated through activation of diphtheria toxin-A gene. E2F2 expression resulted in a 10-39 
fold increase in BrdU uptake and a 34% increase in central RPE cell density. Although in mice 40 
this localised rescue is insufficiently large to be demonstrable by electroretinography, a 41 
measure of massed retinal function, these results provide proof-of-concept for a strategy to 42 




AMD is the leading cause of blindness in the elderly worldwide, affecting 30–50 million 46 
individuals, 14 million of which are blind or severely visually impaired.1-3 Due to the rapidly 47 
aging population, the number of persons suffering from advanced forms of AMD will increase by 48 
50% in 2020.4 Currently, there is neither a preventive or curative treatment for AMD. For non-49 
neovascular AMD affecting the majority of patients (>92%), no established treatment options 50 
exist. For neovascular AMD, the most widely used treatment involves administration of 51 
antibodies against vascular endothelial growth factor (VEGF) to prevent the formation of new 52 
blood vessels. Underlying all forms of AMD is a dysfunctional retinal pigment epithelium (RPE). 53 
RPE function is essential for maintaining photoreceptor health by providing growth factors and 54 
cytokines5, forming the outer blood retina barrier, phagocytosis of photoreceptor outer 55 
segments and processing retinoids for phototransduction. The continual phagocytosis of shed 56 
photoreceptor discs is associated with a high level of oxidative stress that may lead to loss of 57 
RPE.6 The highest turnover rate of shed photoreceptor discs is in the macula where 58 
photoreceptor density is highest.7 In the adult human eye, the RPE is a non-dividing cell 59 
system,8, 9 and death of RPE cells is not compensated by cellular regeneration.7, 10 In retinal 60 
degenerations, when RPE is lost, surrounding RPE cells enlarge to fill the space.11  This increases 61 
metabolic load on individual RPE cells resulting in further damage and loss. Replacing RPE cells 62 
by transplantation or inducing controlled proliferation of RPE cells may prevent disease 63 
progression.  64 
 65 
Various attempts have been made to replace diseased RPE in the central retina, but none so far 66 
has proved efficient and safe enough for standard treatment. Macular translocation surgery 67 
aims to relocate the central retina to an area of healthy RPE.12 Despite a high complication 68 
rate,13 gain of visual function in some patients provides a proof-of-concept that RPE re-69 
population under the macula restores vision.14-17 RPE transplantation, using autologous RPE 70 
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sources such as iris pigment epithelium18 or RPE from the periphery19-21, has been investigated 71 
for over three decades.22 Recently there have been several clinical trials involving RPE derived 72 
from human embryonic stem cells23 or human induced pluripotent stem cells.24, 25 Despite 73 
promising results, to date there is no consensus over the best method to treat RPE defects and it 74 
remains uncertain how effective this approach might be.  75 
 76 
Here we propose a new strategy to regenerate RPE in situ by making use of its natural 77 
proliferative potential. We sought to overcome the intrinsic barriers to RPE proliferation and 78 
induce regeneration by mitosis in vivo using lentiviral vector-mediated transfer of the gene 79 
encoding the transcription factor E2F2, which can induce cells to bypass G1 arrest.25-27 The E2F 80 
transcription factor family and the product of the retinoblastoma tumour suppressor gene (Rb) 81 
can be described as opposing molecules that control the G1 to S phase transition,26 whereby Rb 82 
is recognized as a tumour suppressor and key inhibitor of E2F, a central transcriptional 83 
activator.27 The E2F transcription factor family control a variety of genes involved in DNA 84 
replication such as thymidine kinase, thymidylate synthase, dihydrofolate reductase – virtually 85 
the entire apparatus of initiation factors that assemble a pre-replication complex at the 86 
transition from G1 to S phase.28 While E2F-1 to -4 all induce S phase progression with 87 
decreasing efficacy, E2F1 uniquely also induces apoptosis.29 In this study, we therefore selected 88 
E2F2 for overexpression to overcome cell cycle arrest in RPE cells. We test this concept in vitro, 89 
in wildtype mice and in an inducible RPE-deficient mouse model (RPECreER/DTA)11 and provide 90 
evidence for in situ RPE cell proliferation. 91 
  92 
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Results and Discussion 93 
The effect of E2F2 overexpression was assessed in vitro on ARPE19 cells. Growth arrested 94 
ARPE19 cells, as shown by an absence of nuclear Ki67 (Fig. S1), were transfected with pCMV-95 
E2F2. E2F2 mRNA persisted at a >1000-fold increase 21 days post transfection (Fig. 1a), 96 
inducing E2F2 protein overproduction by 9-fold after 2 days, and 3-fold after 7 days compared 97 
with control plasmid (Fig. 1b,c). E2F2 overexpression coincided with increased protein levels of 98 
proliferation marker Cyclin D1 (Fig. 1b,d). Two days after transfection of growth-arrested 99 
monolayers with pCMV-E2F2, or control plasmid pcDNA3-EGFP, over 86% of cells were Ki67-100 
positive in both groups. However, on day 7 and 14 post transfection, E2F2 overexpression 101 
resulted in a 2.3-fold and 1.7-fold increase respectively in Ki67-positive nuclei compared with 102 
pCDNA3-EGFP controls (P<0.05, t-test; Fig. 1e) suggesting that E2F2 stimulates an increase in 103 
proliferation in vitro.  Similarly, after an initial increase in uptake of bromodeoxyuridine (BrdU), 104 
a synthetic thymidine analogue incorporated into newly synthesized DNA, in both control and 105 
E2F2-transfected cells,  BrdU uptake in E2F2-treated cells increased by 3.5- and 5.4-fold, at 1 106 
and 2 weeks respectively, (Fig. 1f). Together these results suggest that E2F2 overexpression can 107 
lead to specific induction of cell proliferation in contact-inhibited ARPE19 cells. 108 
 109 
To test whether the same approach might be effective in vivo, the E2F2 construct was packaged 110 
into a non-integrating lentiviral vector, LNT-E2F2, and administered subretinally, causing E2F2 111 
overproduction and nuclear localization in the RPE (Fig. 2a). To assess RPE proliferation, 9-112 
week-old wildtype mice received subretinal injections of LNT-E2F2 (2 x 105 infectious particles 113 
per eye). Titre matched LNT-hrGFP and medium injected eyes served as controls (n=4). All mice 114 
received daily intraperitoneal BrdU injections between day 4-10. On day 10, RPE flatmounts 115 
showed co-localized E2F2 and BrdU staining with minimal staining in controls (Fig. 2b). This 116 
experiment was repeated twice with different batches of vector and each showed similar results 117 
(total n=20, Fig. S2a). In the LNT-E2F2 group (Fig. 2c), a significant linear E2F2/BrdU 118 
correlation was observed (Pearson correlation coefficient 0.9170, P<0.0001), while no 119 
6 
correlation was observed for the medium-injected control group (Fig. 2d), indicating that 120 
uptake of the cell proliferation marker is the effect of E2F2 overexpression. Compared with the 121 
control group, there was a 50-fold increase of E2F2-positive cells in the LNT-E2F2 group, and a 122 
10-fold increase in BrdU-positive cells (Fig. 2e). This experiment was repeated twice with 123 
different batches of vector yielding comparable results (total n=20 eyes, Fig. S2b). In 18-month-124 
old mice (n=3 mice for pairwise left-right comparison against LNT-hrGFP), we tested whether 125 
age of the animal may affect the proliferative effect of E2F2 overexpression in vivo. The similar 126 
increase in BrdU uptake upon E2F2 overexpression in young and 18-month-old mice suggests 127 
this approach was not restricted by the age of the recipient (Fig. 2f). 128 
 129 
To assess whether the increase in cell proliferation markers resulted in increased RPE cell 130 
density, 8-week-old adult mice received subretinal injections of LNT-E2F2, LNT-GFP or medium. 131 
Fifty-three phalloidin-stained RPE flatmounts of 30 mice were imaged 10 days after treatment 132 
(Fig. 3a). Only transduced areas around the injection site were evaluated; areas directly 133 
adjacent to the injection site that were severely dysmorphic were excluded. Compared with 134 
controls, LNT-E2F2 treated eyes presented with variable cell size and morphology as would be 135 
expected when existing cells divide in situ and two new cells take up the available space. It 136 
should be noted that the presence of two nuclei constitutes normal morphology for a mouse 137 
RPE cell. Cell outlines were partially disrupted and smaller cells gathered in clusters without 138 
gaps between cells. No overt pathology of the neuroretina was observed in these eyes. RPE cell 139 
density was quantified on masked samples by counting cells outlined by phalloidin staining. 140 
Untreated age-matched eyes served as an additional control. One-way ANOVA revealed highly 141 
significant differences among groups (P=0.0002, Fig. 3b). LNT-E2F2 injected eyes presented an 142 
RPE cell density significantly higher that all three control groups (P=0.0011 - 0.0071, Tukey’s 143 
multiple comparisons test). No significant difference was observed between the control groups 144 
(P>0.6). These data reveal that lentiviral-mediated E2F2 overexpression in the RPE can induce 145 
an increase in RPE cell density by about 20% in wildtype RPE. 146 
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We next investigated possible effects of LNT-E2F2 injection and the resulting increase in RPE 147 
density upon the function of the overlying photoreceptors and gross structure of the 148 
neuroretina. As before 8-week-old adult mice received subretinal injections of LNT-E2F2, LNT-149 
GFP or were left uninjected. Retinal function was then assessed by electroretinography (ERG) at 150 
10 and 30 days post injection (DPI) and tissue collected for histological analysis at both 151 
timepoints. Analysis of the ERG data revealed no significant differences between the LNT-E2F2 152 
and LNT-eGFP treated groups at either timepoint under both photopic (Fig. S3a) and scotopic 153 
(Fig. S3b) conditions. Additionally, histological assessment of neuroretina revealed no apparent 154 
differences in retinal morphology between the injected groups at either timepoint (Fig. S3c). In 155 
all examined eyes, retinal morphology appeared normal. 156 
 157 
To test whether E2F2 overexpression can also increase cell density in diseased RPE, we 158 
assessed LNT-E2F2 administration in double-transgenic RPECreER/DTA mice. These carry a 159 
tamoxifen-inducible Cre recombinase driven by the RPE-specific monocarboxylate transporter 160 
3 (SLC16A8) promoter, and a diphtheria toxin A chain (DTA) gene rendered transcriptionally 161 
silent by a floxed stop sequence. Activation of Cre by tamoxifen injection induces DTA 162 
expression, causing partial RPE cell loss. Four double transgenic RPECreER +/-/DTA+/- and four 163 
wildtype mice received intraperitoneal tamoxifen injections (postnatal days 12–24) to induce 164 
RPE ablation in the transgenic mice only. At four months of age, RPE showed polymorphous 165 
cells with increased cell size compared to wildtype RPE, but the monolayer remained intact 166 
without holes (Fig. 4a). Mean cell density was reduced by 15±5% (P=0.0082, Fig. 4b). Regional 167 
analysis revealed that the reduction in cell density in transgenic compared to wildtype mice was 168 
most pronounced in the central RPE, where there was a 24±10% decrease (P=0.0231, Fig. 4c), 169 
in line with our previous findings.11  170 
 171 
RPE damage was induced in 4 transgenic mice as described above. At 4 months, treatment 172 
vector LNT-E2F2 and control vector LNT-GFP were injected subretinally into right and left eyes, 173 
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respectively. Animals received intraperitoneal BrdU injections daily from day 4 to day 10 174 
afterwards. On day 10, RPE-choroid-sclera complexes were immunostained for BrdU and ZO-1 175 
and flatmounted. We analysed both treated and untreated areas, i.e. areas outside the injection 176 
bleb, of the flatmounts throughout all eyes of both groups, as shown schematically in Fig. 5a 177 
(injection sites were excluded). In RPECreER/DTA transgenic LNT-E2F2 treated eyes, we observed 178 
BrdU uptake comparable with wildtype C57BL6/J mice after LNT-E2F2 treatment, while LNT-179 
GFP injected control eyes showed almost no BrdU uptake (Fig. 5b,c). LNT-E2F2 treatment of 180 
RPECreER/DTA mice increased BrdU uptake by 9-fold±3.4 (mean ±SD, P=0.0173, paired t-test, 181 
n=4 eyes). Following LNT-E2F2 treatment, overall cell density was increased 20±11% (mean 182 
±SEM) compared with control vector. However, this did not reach statistical significance 183 
(P=0.2043, unpaired t-test). Regional analysis revealed that the largest increase in cell density 184 
was in the centre in RPE ablated mice (Fig. 5d). In the central retina where Cre-induced 185 
degeneration was most prominent, we saw a significant increase in cell density of 34±10% after 186 
E2F2 overexpression (P=0.0458). In the mid-periphery and periphery, smaller non-significant 187 
increases in cell density were observed.  188 
 189 
RPE cells have an inherent capacity to proliferate. In vitro, mammalian RPE cells can be cultured 190 
for up to six months, undergoing several population doublings.30 In vivo, RPE cells can 191 
proliferate as a natural reaction to disruption of the subretinal space during retinal 192 
detachment.31-33 A necessary precondition for this kind of proliferation is disruption of cell-cell 193 
junctions to overcome contact inhibition. By E2F2 gene transfer, we were able to induce 194 
proliferation in situ, without disruption of the RPE monolayer, and we showed that the biggest 195 
effect was achieved in the RPE area with the lowest cell density. 196 
 197 
Subretinal injection itself is not free of trauma and might have induced some proliferation. 198 
However, injection of LNT-E2F2 vector caused limited BrdU uptake in cells evenly distributed 199 
throughout the injection area. Cells in the E2F2 treatment group showed variable cell size and 200 
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smaller cells gathered in clusters, potential signs of toxicity or the results of replication. If 201 
toxicity were the prevailing factor for altered morphology, we would expect dying cells to leave 202 
the monolayer and leaving gaps between cells. Since the RPE monolayer remained intact, we are 203 
confident that the cell morphology in the E2F2 treated RPE reflects the effects of cell division. 204 
BrdU uptake is a sign of DNA synthesis and therefore cell cycle progression from G1 to S phase, 205 
but this does not always signify completion of mitosis. We therefore focused on cell density as 206 
the main endpoint. To compensate for any effect of the injection trauma, we added untreated 207 
eyes that never received any subretinal injection as controls. Untreated eyes showed a slightly 208 
higher cell density compared with the controls injected with LNT-GFP or medium, possibly 209 
indicative of minor, injection-related cell loss, but this was not significant. The highest cell 210 
density was seen in the LNT-E2F2 treatment group, showing a significant increase of 14% 211 
compared with untreated RPE and 21% compared with control transduced RPE.  212 
As for 9 week-old adult mice, we observed similar cell cycle progression in mice older than 18 213 
months, which corresponds to a human age of >50 years, when age-related changes of the 214 
macula become apparent. However, mouse RPE does not show age-related changes comparable 215 
to human, and any extrapolation of our findings to patients with AMD calls for caution. Older 216 
human RPE cells in the central macula exposed to life-long oxidative stress may not be capable 217 
of undergoing a full cell division. Del Priore et al. found that the proportion of apoptotic cells in 218 
human RPE increased significantly with age, possibly amounting to a loss of 20% of the macular 219 
RPE per decade in older human eyes.10 Interestingly, apoptosis was confined to the central 220 
region. In apparent contrast to Del Priore, Ach et al. showed that in the centre, human RPE cell 221 
density remains stable over lifetime.34 This discrepancy may be explained by RPE undergoing a 222 
life-long re-arrangement, for example by migration from the periphery, possibly in combination 223 
with mitosis. In human adult RPE mitosis is detected at a very low rate, but only in the 224 
periphery.10, 35 By E2F2 transfer, we may be harnessing a natural process of mitotic regeneration 225 
that is latent in the adult mammalian retina. In the transgenic mouse model, which we utilize as 226 
a model for RPE cell disease, no spontaneous mitotic regeneration was detected, instead cells 227 
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expanded to up to 20 times their normal size, similar to what is observed in AMD patients.32 228 
Furthermore, we observe the presence of BrdU positive cells throughout the treatment area and 229 
the greatest proliferative effect of E2F2 transfer in the centre where cell density was lowest. 230 
This indicates that the E2F2 triggers mitosis of cells in situ rather than recruiting cells from the 231 
periphery.  232 
 233 
We and others have previously established that alterations made to the state of the cell cycle or 234 
cell-cell adhesion signalling pathways can result in de-differentiation of the RPE and the cells 235 
may undergo epithelial mesenchymal transition. This results in a dramatic loss of RPE cell 236 
identity both in terms of cell morphology and gene expression profile36, 37. Whilst transduced 237 
RPE (either by LNT-E2F2 or LNT-GFP) do display some morphological differences from 238 
untreated cells, the changes observed are much less severe than those seen in EMT in which 239 
cuboidal cell shape is lost. However, to examine whether any de-differentiation was occurring at 240 
the level of gene expression, we performed immunohistochemical staining for RPE65, a retinoid 241 
isomerohydrolase vital for RPE function. Transduction of the RPE with lentiviral vectors results 242 
in very sharp delineation of the transduced area. At 10 days post-injection the RPE65 signal was 243 
relatively homogenous across the boundary between the transduced and untransduced area in 244 
both LNT-E2F2 and LNT-GFP injected eyes, indicating little loss of RPE cell identity in 245 
transduced cells (Fig 6). 246 
 247 
Whilst this study primarily focused upon the direct effect of E2F2 overexpression within the 248 
RPE, we also found no indication of an indirect effect upon the overlying photoreceptors, in 249 
terms of either structure or function within wildtype mice. It should be noted, however, that 250 
loss of vision in conditions such as AMD is thought to be a result of photoreceptor cell death as a 251 
consequence of RPE pathology. Any therapeutic strategy aiming to preserve or restore RPE 252 
integrity must therefore be applied prophylactically and the degree of photoreceptor 253 
degeneration will be critical in defining the treatment window. 254 
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 255 
Although no sign of neoplastic growth was seen over the timeframes used in these experiments, 256 
continuous E2F2 overexpression may lead to a tumorigenic event, as the protein in implicated 257 
in retinoblastoma and glioblastoma38. In these proof-of-concept experiments, we used non-258 
integrating vectors resulting in episomal transgene copies, which will be diluted from the 259 
nucleus with every cell division. It is, however, possible that a temporary over-expression of 260 
E2F2, as we attempted here, could result in the establishment of a positive feedback loop that 261 
maintains the transduced cells within the cell cycle.39 It may therefore be necessary to 262 
characterise more fully the effect of transient E2F2 overexpression upon the RPE cell cycle in 263 
vivo and implement additional safety measures. For example, an inducible promoter could be 264 
used to further control duration of expression, or a reverse transcriptase-defective lentiviral 265 
vector could be used, where reverse transcription of the transgene into DNA is prevented and 266 
the protein translated transiently from RNA templates.40  267 
 268 
In summary, our work shows that viral vector mediated gene delivery of E2F2 can induce 269 
proliferation in healthy and diseased RPE cells in vivo and that this approach can increase cell 270 
density of RPE cells preferentially in areas of low density, where contact inhibition may be 271 
lowest. In mice, where assessments of vision are generally massed retinal responses, this 272 
localised rescue would not be sufficiently large to be able to detect improved vision. However, in 273 
the human eye, this approach may provide an alternative to RPE cell transplantation by paving 274 
the way for an in situ regenerative approach to treat RPE cell pathology in Stargardt disease and 275 
age-related macular degeneration (AMD).  276 
 277 
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Materials and Methods 278 
Recombinant non-integrating lentiviral vectors 279 
Self-inactivating VSV-G pseudotyped lentiviral vectors were produced using the packaging 280 
plasmid pCMVΔR8.74D64V as described previously.41, 42 After transfection of HEK293T cells, 281 
vector particles were harvested from culture supernatant at 48 and 72 h post transfection and 282 
purified / concentrated by filtration (0.45 µm) and ultracentrifugation and suspended in serum-283 
free OptiMEM at 107 to 108 transducing units/mL. See Supplementary Methods for details. 284 
 285 
In vivo experiments 286 
All animals were cared for in accordance with the UK Animal Scientific Procedures Act 1986 and 287 
procedures were in accordance with the ARVO Statement for the Use of Animals in Ophthalmic 288 
and Vision Research. Female wild-type C57BL6/J mice (Harlan Laboratories, Bicester, UK) were 289 
used aged 6-8 weeks or up to 18 months. In transgenic male and female RPECreER/DTA mice11 290 
RPE degeneration was induced by three intraperitoneal injections of 50µg tamoxifen during 291 
postnatal days 12–24. Transscleral subretinal injections were performed as previously 292 
described43, 44, see Supplementary Methods. Per eye, two injections of 2 µl of viral suspension (5 293 
x 107 vector particles/mL) were injected into the subretinal space. Group sizes were based on 294 
estimated variation and effect size. Animals and treatment eyes were not randomised.  295 
 296 
Cell counts 297 
Quantification of RPE cell density was done on confocal micrographs of masked samples by 298 
manually counting cells outlined with phalloidin or ZO-1 (using NIH ImageJ software, 299 
http://rsbweb.nih.gov/ij/, Version 1.46a). Masking was done on two levels: the flatmount slides 300 
were masked before imaging by an independent observer. Image acquisition and image analysis 301 
was done by different researchers, and the image labels were again masked. 6 micrographs per 302 
eye acquired in a standard pattern were counted and averaged.  303 
13 
 304 
Statistical analysis 305 
Student’s t test or analysis of variance tests were used as indicated for each experiment in the 306 
figure legends. Variance within groups was estimated to determine similarity between groups 307 
being compared. P<0.05 was deemed significant.  308 
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 Figure legends 446 
 447 
Fig. 1. E2F2 overexpression induces proliferation in a growth arrested, confluent monolayer of 448 
ARPE19 cells in vitro.  449 
a. 21 days post-transfection with pCMVHA-E2F2, E2F2 mRNA is >1000-fold increased compared 450 
with controls transfected with pcDNA3-EGFP (mean + SD).  451 
b, c. Increase in protein levels of E2F2 compared with control, assessed by Western blot (9-fold 452 
increase after 2 days, 3-fold increase after 7 days; 2-tailed t-test; densidometric quantification, 5 453 
min and 30 min indicate different exposure times, mean + SD).  454 
b, d. Levels of proliferation marker Cyclin D1 increased following E2F2 overexpression (2- and 455 
3-fold, on day 2 and 7, respectively). 456 
e. E2F2 overexpression induces Ki67 expression. On day 7 and 14 post transfection, E2F2 457 
caused a 2.3-fold and 1.7-fold increase in Ki67 positive nuclei compared with controls (40% vs. 458 
18% and 7% vs. 4% of total cells; 2-tailed t-test).  459 
f. E2F2 overexpression induces BrdU uptake. BrdU positive nuclei were increased by 3.5- and 460 
5.4-fold at 1 and 2 weeks post transfection, respectively (2-tailed t-test). 461 
 462 
  463 
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Fig. 2. LNT-E2F2 induces BrdU uptake in RPE in vivo.  464 
Wildtype mice received daily intraperitoneal injections of BrdU from day 4 to day 10 after 465 
subretinal injections of vector (n=4 eyes per group from different animals).  466 
a. RPE-choroid-sclera was immunostained for E2F2 (green) and BrdU (red) and flatmounted for 467 
imaging on a confocal laser scanning microscope. Analysis included injected areas, identified by 468 
a demarcation line along the border of the former injection bleb, clearly visible on flatmounts 469 
(outlined by arrowheads), but excluded the injection site with trauma-related artefacts (arrow). 470 
Scale bar = 1mm. 471 
b. In LNT-E2F2 injected eyes, RPE flat mounts show overexpression of E2F2 co-localizing with 472 
BrdU. Controls show very limited staining for E2F2 (medium) or BrdU (medium, LNT-GFP). 473 
Scale bar = 75 µm. 474 
c, d. Counts of E2F2 positive nuclei were correlated with counts of BrdU positive nuclei for each 475 
high power microscopic field (HPF, total of 20 HPFs, 5 per eye). In the LNT-E2F2 group, a high 476 
linear correlation was observed (Pearson correlation coefficient 0.9170, r2=0.841, P<0.0001), 477 
while no correlation was observed for the medium injected control group.  478 
e. The LNT-E2F2 injected group showed a significant increase in E2F2 and BrdU staining 479 
compared with both control groups (mice aged 9 weeks, n=4 eyes per group from different 480 
animals, P<0.0001, one-way ANOVA; *** P<0.0001 in Tukey’s multiple comparisons test, no 481 
significant difference between both control groups; bars represent mean ± SD). E2F2 and BrdU 482 
positive nuclei were counted in 5 HPF per eye and averaged. 483 
f. 18 months old mice (n=3 mice for pairwise left-right comparison) demonstrate a similar 484 
increase in BrdU uptake upon E2F2 overexpression (* P=0.0463, 2-tailed paired t-test; bars 485 
represent mean ± SD).  486 
 487 
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Fig. 3. E2F2 overexpression increases RPE cell density in vivo.  488 
a. Immunofluorescence staining of f-actin of flatmounted RPE shows cell outlines of the RPE 489 
monolayer. E2F2 overexpression in the treatment group was verified by immunostaining. Scale 490 
bar = 100 µm. 491 
b. Quantification of RPE cell density was done on masked samples by counting cells. 6 492 
micrographs per eye were counted and averaged, for each condition n=15 eyes from different 493 
animals, for medium controls n=8. Numbers in graph represent mean cell density; error bars 494 
represent SD. One-way ANOVA revealed highly significant differences among groups 495 
(P=0.0002). LNT-E2F2 treatment increased cell density by 17 ±13% compared to LNT-GFP, by 496 
21 ±14% compared to medium injection, and by 14 ±7% compared to untreated eyes (Tukey’s 497 
multiple comparisons test). 498 
 499 
Fig. 4. The RPECreER/DTA mouse line shows reduced RPE cell density most prominently in the 500 
centre. 501 
a. ZO-1 staining reveals increased cell size and polymorphism in the RPE ablated group in 502 
various locations along the central to peripheral axis. Scale bar = 50 μm. 503 
b. Overall density was reduced by 15 ±5% (mean ± SEM, range 5 – 25%, values in graph above 504 
the x axis are mean ±SD, n=8 eyes per group, P=0.0082, 2-tailed t-test). 505 
c. Reduction was most pronounced in the central RPE, showing a 24 ±10% decrease (mean 506 
+SEM, n=8 eyes, P=0.0231, 2-tailed unpaired t-test). 507 
 508 
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Fig. 5. LNT-E2F2 induces increased BrdU uptake in RPECreER/DTA mice and increases RPE cell 510 
density. 511 
a. Schematic representation of the RPE flatmounts to illustrate regional analysis of cell density. 512 
b. Treatment vector LNT-E2F2 and control vector LNT-GFP were injected in right and left eyes, 513 
respectively, of RPECreER/DTA mice (n=4 eyes per group). Mice received daily intraperitoneal BrdU 514 
injections on day 3 to 9 post injection. BrdU staining (red) is shown in representative RPE flatmounts. 515 
Scale bar = 500 µm.  516 
c. Quantification of BrdU positive nuclei in 6 micrographs per flatmount revealed a significant 517 
increase compared to LNT-GFP treated controls (P=0.0173, 2-tailed paired t-test, n=4 eyes per 518 
group, bars show mean ± SEM). 519 
d. Regional analysis of cell density shows a statistically significant increase in the centre where RPE 520 
degeneration was strongest. Here, an average increase of 34 ±10% was observed (P=0.0458, 2-tailed 521 
paired t-test, n=4 eyes per group, bars show mean +SEM). 522 
 523 
Fig. 6. Lentivirus-mediated overexpression of E2F2 does not lead to dedifferentiation of RPE cells, 524 
as evidenced by the presence of RPE65  525 
Staining for RPE-specific protein RPE65 in RPE flatmounts 10 days after subretinal administration of 526 
LNT-E2F2 showed no consistent decrease in cells positive for E2F2 protein in the nucleus, compared 527 
with E2F2 negative cells. RPE transduced with LNT-GFP control virus and no-primary control samples 528 
are provided as controls. Scale bar = 50 µm 529 
  530 
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Supplementary Material 531 
 532 
Fig. S1. Growth arrest in ARPE19 cells. 533 
a. ARPE19 cells were cultured in starvation medium containing 1 % FBS. Over the course of 2–3 534 
weeks, expression of tight junction marker ZO-1 (green) increased while the proportion of cells 535 
positive for proliferation marker Ki67 (red) decreased. Scale bar = 100 µm. 536 
b. The proportion of Ki67 positive cells showed inverse correlation to the total number of cells, 537 
indicating growth arrest.  538 
 539 
Fig. S2. LNT-E2F2 induces BrdU uptake in RPE in vivo.  540 
Wildtype mice aged 12 weeks received subretinal injections of non-integrating LNT-E2F2 vector 541 
(2 x 105 infectious particles per eye) in the superior and inferior hemisphere of the eye. Titre 542 
matched LNT-hrGFP and medium (OptiMEM) injected eyes served as controls (n=3 eyes per 543 
group from different animals). All mice received daily intraperitoneal injections of BrdU from 544 
day 4 onwards until they were sacrificed 8 days post injection.  545 
a. RPE-choroid-sclera was immunostained for E2F2 and BrdU and flatmounted for imaging on a 546 
confocal laser scanning microscope. Analysis included injected areas only, injection sites with 547 
trauma-related artefacts were excluded. In LNT-E2F2 injected eyes, RPE flat mounts show 548 
overexpression of E2F2 co-localizing with BrdU. Controls show very limited staining for E2F2 549 
(medium) or BrdU (medium, LNT-GFP). Scale bar = 250 µm. 550 
b. The LNT-E2F2 injected group showed a significant increase of E2F2 and BrdU staining 551 
compared to both control groups (P<0.0005, one-way ANOVA; ** P<0.005, *** P<0.0005 in 552 
Tukey’s multiple comparisons test, no significant difference between both control groups; bars 553 
represent mean ± SD). E2F2 and BrdU positive nuclei were counted in 5 high power microscopic 554 
fields (HPF) per eye and averaged.  555 
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Fig. S3. LNT-E2F2 does not affect photoreceptor function and histology. 556 
Wildtype mice aged 8 weeks received subretinal injections of non-integrating LNT-E2F2 vector 557 
(2 x 105 infectious particles per eye) in the superior and inferior hemisphere of the eye. Titre 558 
matched LNT-GFP and uninjected eyes served as controls (n=8 eyes per group from different 559 
animals). 560 
a. Photopic [10cd.s/m2] ERG b-wave amplitudes in LNT-E2F2 and LNT-GFP injected eyes at 10 561 
and 30 days post injection (DPI). Uninjected control also shown for reference. No significant 562 
differences were found (One-way ANOVA with Tukeys multiple comparisons test). 563 
b. Scotopic [0.01cd.s/m2] ERG b-wave amplitudes in LNT-E2F2 and LNT-GFP injected eyes at 10 564 
and 30 days post injection (DPI). Uninjected control also shown for reference. No significant 565 
differences were found (One-way ANOVA with Tukeys multiple comparisons test). 566 
c. Representative retinal histology of LNT-E2F2 and LNT-GFP injected eyes at 10 and 30 days 567 
post injection (DPI). All images taken from the mid superior retina ~600µM from the optic 568 


































Recombinant non-integrating lentiviral vectors 
Self-inactivating VSV-G pseudotyped lentiviral vectors were produced as described previously1 
using the following plasmids: packaging plasmid pCMVΔR8.74D64V,2 envelope plasmid 
pMD2.G,3 and transfer vector based on pHR’SIN-cPPT.4 Plasmids were prepared at a molar ratio 
of 50 : 17.5 : 32.5, and 80 µg of total plasmid DNA per 150 cm2 culture dish was used for 
transient transfection of near-confluent HEK-293T cells using PEI. Vector particles were 
harvested from culture supernatant at 48 and 72 h post transfection and purified / 
concentrated by filtration (0.45 µm) and ultracentrifugation. Vector particles were suspended in 
serum-free OptiMEM (Life Technologies, Paisley, UK), which was also used for control medium-
only subretinal injections. Vector titres were determined by transduction of 293T cells with 
serial vector dilutions (LNT-GFP) or by quantification of reverse transcriptase using the Reverse 
Transcriptase Assay colorimetric kit (Roche). Vector concentration was 107 to 108 transducing 
units/mL.  
For E2F2 cDNA transduction, E2F2 was inserted into the transfer plasmid behind the CMV 
promoter by restriction enzyme digestion and directional ligation. The resulting vector was 
named LNT-E2F2. Human full-length E2F2 cDNA (1313 bp) was derived from plasmid pCMV-
E2F2, kindly provided by Dr Nancy Joyce, Schepens Eye Research Institute, Harvard Medical 
School, Boston, USA.5, 6 LNT-GFP, based on the same production plasmids, was used as control 
vector delivering hrGFP.7  
 
In vitro experiments 
ARPE19 cells (ATCC CRL-2302, Manassas, VA) were cultured in DMEM/F12 containing 100 
U/mL penicillin and 100 µg/mL streptomycin (all from PAA Laboratories, Pasching, Austria) 
and 10% fetal bovine serum (FBS, Biochrom, Berlin, Germany). Cells were seeded in equal 
densities to 24 well plates and after 24 hours, medium was changed to 1% FBS. After 2 weeks 
with medium exchange twice a week, a confluent monolayer with ZO-1 positive cell borders and 
no mitotic activity was formed (cf. Fig. S1). At this stage, cells were used for transfection using 
linear polyethylenimine (PEI, Polysciences, Eppelheim, Germany) pre-incubated with plasmid at 
a ratio of 2.25 : 1 (w/w) for 20 min and added to cells for 24 h. Plasmids were obtained from 
Addgene, Cambridge, MA: pCMVHA-E2F2 (plasmid #24226, delivering E2F2 under CMV 
promoter)8, pcDNA3-EGFP (#13031, delivering eGFP under CMV promoter), pCMV-Neo-Bam 
(#16440, empty plasmid).  
 
In vivo experiments 
All animals were cared for in accordance with the UK Animal Scientific Procedures Act 1986 and 
procedures were in accordance with the ARVO Statement for the Use of Animals in Ophthalmic 
and Vision Research. Female wild-type C57BL6/J mice (Harlan Laboratories, Bicester, UK) were 
used aged 6-8 weeks or up to 18 months. In transgenic male and female RPECreER/DTA mice,9 
RPE degeneration was induced by three intraperitoneal injections of 50µg tamoxifen during 
postnatal days 12–24.  
Animals were anaesthetised with intraperitoneal injection of medetomidine hydrochloride (1 
mg/ml, Domitor, Pfizer Pharmaceuticals, Walton Oaks, UK) and ketamine (100 mg/ml, Fort 
Dodge Animal Health, Southampton, UK) and sterile water in the ratio 5:3:42. Transscleral 
subretinal injections were performed as previously described4, 10 under direct vision of the 
fundus with an operating microscope. Per eye, two injections of 2 µl of viral suspension (5 x 107 
vector particles/mL) were injected into the subretinal space causing a localised retinal 
detachment. For BrdU labelling experiments, mice received daily intraperitoneal injections of 2 
mg BrdU (Sigma-Aldrich, Steinheim, Germany; diluted to 10 mg/ml in PBS) from day 4 post 
subretinal injection onwards.  
 
Electroretinogram (ERG)  
All animals were dark adapted overnight prior to ERG recordings. Animals were anesthetised, 
pupils were dilated using 2.5% phenylephrine and 1.0% tropicamide and ERGs were recorded 
using commercially available equipment (Espion E2, Diagnosys, LLC, MA). A series of scotopic 
recordings at different light intensities were obtained from each eye, and 0.01 cd s−1 m−2 was 
selected as the intensity for analysis. Photopic recordings were performed following 5 min light 
adaptation interval at a light intensity of 30 cd m−2. This level was also used as background light 
for the duration of photopic recordings. A series of photopic recordings at different light 
intensities were obtained from each eye, and 10 cd s−1 m−2 was selected as the intensity for 
analysis. After the procedure anaesthesia was reversed and the mice allowed to recover.  
 
Reverse transcription polymerase chain reaction (RT-PCR) 
Cells were washed and lysed for total RNA extraction using a silica membrane / salt buffer 
system (RNeasy Mini Kit, Qiagen, UK). Equal amounts of RNA were immediately reverse 
transcribed into cDNA using the QuantiTect Reverse Transcription Kit (Qiagen) following the 
manufacturer’s directions. Primers for E2F2 (5’-GCATCTATGACATCACCAACG-3’ and 5’-
TCAAACATTCCCCTGCCTAC-3’) were used for standard qPCR reactions with a dark quencher 
dye (Roche, Mannheim, Germany). The PCR was run on an ABI Prism 7900HT Fast Real-time 
Sequence Detection System (Life Technologies, Paisley, UK). Three identical replicates were run 
for each sample, and the averaged CT value was used for relative quantification using the 
comparative CT method against HPRT as reference gene (CT method).  
 
Western blot 
Western blots were prepared as described previously11 using the following primary antibodies: 
E2F2 (sc-633, Santa Cruz Biotechnology, Heidelberg, Germany), Cyclin D1 (2978, Cell Signaling 
Technology, Danvers, MA), GAPDH (MAB374, Merck Millipore, Darmstadt, Germany).  
 
Immunofluorescence microscopy 
ARPE19 cells grown on uncoated glass coverslips were fixed in 2% PFA for 10 min. Whole mice 
eyes were enucleated and fixed in 4% PFA for 1 h. For RPE flat mounts the ocular adnexa and 
anterior segment were removed under a dissecting microscope. Vitreous and retina were 
carefully detached and the remaining RPE-choroid-sclera eye cups processed for 
immunochemistry. Cells and eye cups were blocked in 5% normal goat serum, 1% FBS, 0.2% 
Triton-X in PBS. Primary antibody was incubated overnight at 4°C in blocking solution: E2F2 
(1:200, #sc-632, Santa Cruz Biotechnology, Heidelberg, Germany), BrdU (1:100, #6326, Abcam, 
Cambridge, UK), Ki67 (1:100, #P6834, Sigma-Aldrich), ZO-1 (1:50, #40-2200, Life Technologies, 
Paisley, UK). F-actin was stained with phalloidin-TRITC (50µg/ml, #P1951), nuclei with DAPI 
(5µg/ml, #D9542, both Sigma-Aldrich). After washing three times with PBS, conjugated 
secondary antibodies (Alexa Fluor 488, 546, 633, Life Technologies; 1:500 in blocking solution 
for 1 h at room temperature) were used. Eye cups were then flattened out on a glass slide, RPE 
facing upwards, with a paintbrush, and covered with a glass coverslip using 40µL of fluorescent 
mounting medium (DAKO, Ely, UK). For retinal sections, whole eyes were embedded in O.C.T. 
medium (R.A. Lamb) and frozen in isopentane, precooled in liquid nitrogen. Specimens were 
stored at - 20 °C and 20 μm thick sections were cut using a Bright cryostat. Slides were stored at 
-20 °C. Sections were air dried for 10 min and marked with a hydrophobic pen before staining 
with DAPI. All images recorded with a confocal laser scanning microscope (Leica DM5500Q, 
Leica Microsystems, Wetzlar, Germany). Pictures shown are z-stack projections of multiple 
images covering the entire tissue depth in the z-axis.  
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 Fig. S3. LNT-E2F2 does not affect photoreceptor function and histology. 
Wildtype mice aged 8 weeks received subretinal injections of non-integrating LNT-E2F2 vector 
(2 x 105 infectious particles per eye) in the superior and inferior hemisphere of the eye. Titre 
matched LNT-GFP and uninjected eyes served as controls (n=8 eyes per group from different 
animals). 
a. Photopic [10cd.s/m2] ERG b-wave amplitudes in LNT-E2F2 and LNT-GFP injected eyes at 10 
and 30 days post injection (DPI). Uninjected control also shown for reference. No significant 
differences were found (One-way ANOVA with Tukeys multiple comparisons test). 
b. Scotopic [0.01cd.s/m2] ERG b-wave amplitudes in LNT-E2F2 and LNT-GFP injected eyes at 10 
and 30 days post injection (DPI). Uninjected control also shown for reference. No significant 
differences were found (One-way ANOVA with Tukeys multiple comparisons test). 
c. Representative retinal histology of LNT-E2F2 and LNT-GFP injected eyes at 10 and 30 days 
post injection (DPI). All images taken from the mid superior retina ~600µM from the optic 
nerve head. Scale bar = 100 µM. 
 
